Head-to-head evidence
Ambroxol vs PR001 (LY3884961)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: GBA1/glucocerebrosidase · full Parkinson's Disease pipeline
Ambroxol
Developed by Agyany Pharma Ltd
NCT05830396 · Phase 2/3 · status unknown
This is a randomized, placebo-controlled trial with full blinding of participants, care providers, and assessors, using a validated Parkinson's motor rating scale as its primary endpoint. Results have not yet been posted, so whether ambroxol improved motor outcomes compared with placebo is not yet known.
Next expected readout: February 2029 · NCT05778617 (registry estimate)
PR001 (LY3884961)
Developed by Prevail Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2031 · NCT04127578 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ambroxol's landscape · PR001 (LY3884961)'s landscape